Tuesday, July 16, 2019
Hoth Therapeutics, Inc., a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it has entered into an exclusive license option agreement with the George Washington University (GW) pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer.
Under the terms of the agreement, Hoth has an option to exclusively license two U.S. patents covering methods of using Aprepitant or other drugs that inhibit neurokinin-1 (NK-1) receptor function.
This agreement complements the rights provided to Hoth under the recently announced research collaboration with inventor William B. Weglicki, M.D.'s laboratory at GW, which includes an option for Hoth to license any future inventions that may arise from the ongoing Hoth-funded studies at GW.
Should Hoth choose to license a product for further development and sales, the company will reward GW with financial milestones and royalties. Hoth and Dr. Weglicki see potential for a significant impact on ability of cancer patients to complete their prescribed treatment regimens.
